(PRWEB) April 25, 2005
The Vitamin C Foundation has announced the debut of Cardio-C, its new dietary supplement for preventing and healing cardiovascular disease caused by elevated lipoprotein(a), or Lp(a), cholesterol in the blood.
In 1994, Linus Pauling and associates informed the world that non prescription substances, they called "Lp(a) binding inhibitors", prevent cardiovascular disease and will destroy existing atherosclerotic plaque. PaulingÂs rationale explains why the Lp(a) binding inhibitors, vitamin C and the essential amino acid lysine, exert such a strong anti-CVD effect inside human arteries. These substances diminish cellular growth which, if left unchecked, narrow the arteries, decreases blood flow and increases the chance of heart attack or stroke.
"People have a right to be skeptical," says Owen Fonorow, co-founder of the Vitamin C Foundation. "Scams abound and people donÂt know what to believe and often rely on their doctors. Most highly educated people think it impossible that heart disease could be caused by a vitamin deficiency, and the entire medical profession and pharmaceutical industry somehow missed it. However, the idea that a lack of vitamin C causes heart disease is not new. For some reason the early work, and the later Pauling/Rath theory and experiments, are ignored by medical science. We are thankful that Linus Pauling decided to film a lecture making these ideas available on video."
According to Pauling, the Lp(a) binding inhibitor effect is two-pronged.
#1. vitamin C and lysine stimulate the production of collagen. An increased supply of collagen prevents the onset or spread of cardiovascular disease by healing arterial lesions that are caused by normal wear and tear.
#2. Lp(a) binding inhibitors may reverse atherosclerosis by inactivating the affinity that Lp(a) cholesterol has for the amino acid lysine. The second action of binding inhibitors disrupts the formation of the plaque.
"These two complementary actions do not present the same risk that often accompanies prescription drugs and/or approved medical treatments for CVD," states Fonorow. "There are now thousands of reports referring to the plaque-destroying effect of the Pauling Therapy. After ten years, there have been no reports of adverse reactions, even in severely incapacitated patients."
The new Cardio-C is designed mainly as a preventive. It is a powder that, when added to fluid, makes a completely safe, pleasant-tasting drink. PaulingÂs therapy in this form avoids one common obstacle to public acceptance of the protocol: the large number of daily pills.
Cardio-C is a potent Lp(a) binding inhibitor. Its major component is Vitamin C Foundation-approved ascorbic acid, the most biologically active form of vitamin C. Cardio-C provides PaulingÂs preventative dosage of the amino acid lysine and also includes proline, but it does not contain other "extra" ingredients, making it less costly. It is well-suited to those already taking more recognized heart remedies, such as vitamin E, magnesium and CoQ10.
For more information and to order visit http://www.vitaminCfoundation.org or call 1-281-443-3634.
Basis for the Pauling/Rath Discoveries
Cardiovascular related health problems comprise one-half of all causes of death in the USA. In 1994 Linus Pauling, Ph.D., and his associate Matthias Rath, MD, patented Lp(a) Binding Inhibitors for the prevention and reversal of common cardiovascular disease caused by a sub-clinical vitamin C deficiency (chronic scurvy). Previously, these two scientists had long advocated high-dose vitamin C treatment, and they had published a definitive theory as to the root cause and proper treatment for all forms of cardiovascular disease, including congestive heart failure, heart disease and stroke.
More about Lipoprotein(a) Inhibition, Vitamin C and CVD.
Lp(a) is a low density lipoprotein cholesterol molecule. Dr. Rath was a member of a German medical team that in 1989 first determined that human atherosclerotic plaques are composed of Lp(a), not ordinary LDL (the so-called bad) cholesterol. This finding led to hundreds of studies that strongly implicate Lp(a) as a primary risk factor in atherosclerosis, a narrowing of arteries that leads to the most common form of heart disease.
Vitamin C is invaluable in the human bodyÂs production of collagen. Collagen is a protein comprised of coiled lysine and proline fibers forming a helix which increases the tensile strength of blood vessels and other tissue. When the body produces ample collagen, arteries remain healthy, strong and resilient. A lack of collagen causes arteries to become susceptible to the effects of wear and injury. Acute scurvy, the specific vitamin C deficiency disease, is the result of a general breakdown of tissue caused by the lack of collagen.
The Canadian G. C. Willis first suggested in 1952 that plaques form as arteries wear out. In 1989, it was discovered that the body attempts to heal microscopic arterial injuries, called lesions, by producing Lp(a), a sticky molecule with lysine-binding receptors. The Pauling/Rath unified theory identifies Lp(a) as a vitamin C surrogate: The Lp(a) molecule provides stability to arteries in the absence of collagen.
Scientists have determined that lysine and proline residue, from broken collagen strands at the site of the lesion, attract Lp(a). These "sticky" molecules can form a scab in the fast-moving blood stream. More Lp(a) is attracted to the ever- expanding "blockage" as the atherosclerotic plaque grows. Healthy arteries do not have exposed lysine and proline residue and will not attract Lp(a) or form plaques.
High doses of specific nutrients prevent the spread of CVD, and may reverse atherosclerosis. Vitamin C combined with the amino acids lysine and proline create what Pauling and Rath called Lp(a) binding inhibitors. These low-cost, nontoxic substances prevent existing plaques from enlarging because they inactivate the Lp(a) moleculeÂs affinity for lysine. According to the chemist Linus Pauling, the Lp(a) binding inhibitors are solvents that may "destroy existing atherosclerotic plaque."
Linus Pauling made specific dosage-recommendations. A dietary supplement must provide these nutrients at dosages much larger than ordinary vitamins in order to react as an Lp(a) binding inhibitor. At the proper high doses, Lp(a) binding inhibitors become the "Pauling Therapy" in honor of Pauling's contribution.
There are several nutritional substances that reduce Lp(a) blood levels. Vitamin C and vitamin B3 (Niacin) will lower Lp(a) 15-30% in one month. Alternative medical doctors have reported that the amino acid proline lowers Lp(a) significantly over a period from six months to 18 months.
Common cholesterol-lowering drugs called statins are known to elevate serum Lp(a). Advertisements for statin medications in Canadian medical journals must carry this warning.
Pharmacology professor Steve Hickey, Ph.D., co-author of Ascorbate: The Science of Vitamin C, states that over the past 50 years the medical profession has failed to produce the required experiments that may dispute PaulingÂs assertions.
"No one else has replicated the early vitamin C and heart disease research, (that could have been done by almost any cardiologist, from petty cash.) Since Pauling and others have promoted high vitamin C as a cure for heart disease, itÂs ridiculous that a potential cure for the worst killer in the developed nations (atherosclerosis) has not been refuted The fact is that the experiments have been performed on animals and the results show that vitamin C does protect against atherosclerosis, and that it may reverse it. There is additional evidence, from human studies, that is consistent with this interpretation. The question arises as to whether these studies have been performed on humans, and the data withheld? The enemies of Pauling, including the drug companies, would be happy to see the vitamin C hypothesis discredited, for monetary reasons."
Several Lp(a) Binding Inhibitor formulas as dietary supplements are available without prescription.
Interest in the Pauling therapy grows due to the increasing number of favorable accounts of CVD reversals . Many of these detailed first-hand testimonials may be found at PaulingTherapy.com. The listing posted at the Testimonials link includes names and contact numbers.
The Linus Pauling video on Heart Disease: A Unified Theory of Cause and Cure, shows Linus Pauling himself depicting seemingly miraculous reversals of incapacitated CVD patients. The video contains additional information for health professionals and may be obtained from PaulingTherapy.com, or by telephoning Intelisoft Multimedia at 800-894-9025, or 1-630-416-1438 outside the USA.